Comparative Pharmacology
Head-to-head clinical analysis: ADVAIR DISKUS 250 50 versus PREDNISONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADVAIR DISKUS 250 50 versus PREDNISONE.
ADVAIR DISKUS 250/50 vs PREDNISONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fluticasone propionate is a corticosteroid that binds to glucocorticoid receptors, inhibiting inflammatory mediators. Salmeterol xinafoate is a long-acting beta2-adrenergic agonist that relaxes bronchial smooth muscle by increasing cyclic AMP.
Agonist at glucocorticoid receptors, leading to altered gene transcription that results in anti-inflammatory and immunosuppressive effects, including suppression of cytokines, prostaglandins, and leukotrienes.
1 inhalation (fluticasone propionate 250 mcg and salmeterol 50 mcg) twice daily, approximately 12 hours apart, via oral inhalation.
5-60 mg orally once daily or divided twice daily; for acute indications, initial dose 5-60 mg/day; for chronic conditions, lowest effective dose; route: oral, intravenous, intramuscular.
None Documented
None Documented
Clinical Note
moderatePrednisone + Digoxin
"Prednisone may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderatePrednisone + Digitoxin
"Prednisone may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderatePrednisone + Deslanoside
"Prednisone may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderatePrednisone + Acetyldigitoxin
"Prednisone may decrease the cardiotoxic activities of Acetyldigitoxin."
Fluticasone propionate: 14-17 hours (terminal). Salmeterol: 5.5 hours (terminal). The fluticasone half-life supports twice-daily dosing with potential accumulation.
Terminal half-life: 2-3 hours (plasma); clinical effects persist for 12-36 hours due to intracellular actions and active metabolite prednisolone (half-life 3-4 hours).
Fluticasone propionate: <5% renal (as metabolites), majority biliary/fecal. Salmeterol: 57% renal (as metabolites), 30% fecal.
Renal: <10% as unchanged drug; hepatic metabolism to inactive glucuronide and sulfate conjugates; fecal: ~20-30% via biliary elimination.
Category C
Category D/X
Corticosteroid/LABA Combination
Corticosteroid